My guess is that Malone might getting more expensive because of the accounting complexities (derivatives, Bio Art consolidation and structure) and the restatements. There aren't a lot of options. I am betting we may see another 10KA before we see the Q's. Switching firms buys them a few more months in filing.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.